Nebenwirkungen · Xeljanz
XELJANZ 11 mg prolonged-release tablets · Abschnitt 4.8 · PDF-Seite 64
HOS-136432 · Präparat HOS-097868
Neoplasms Lung cancer Lymphoma benign, Non-melanoma skin malignant and cancers unspecified (incl cysts and polyps) Blood and Lymphopenia Leukopenia lymphatic system Anaemia Neutropenia disorders Immune system Hypersensitivity disorders * Angioedema* Urticaria* Metabolism and Dyslipidaemia nutrition Hyperlipidaemia disorders Dehydration Psychiatric Insomnia disorders Nervous system Headache Paraesthesia disorders Cardiac disorders Myocardial infarction Vascular Hypertension Venous disorders thromboembolism** Respiratory, Cough Dyspnoea thoracic and Sinus congestion mediastinal disorders Gastrointestinal Abdominal pain disorders Vomiting Diarrhoea Nausea Gastritis Dyspepsia Hepatobiliary Hepatic steatosis Liver function disorders Hepatic enzyme test abnormal increased Transaminases increased Gamma glutamyl- transferase increased
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T11:44:00Z · SHA-256 7688e3919c1d73c913068635dc81aca63eecf39ee03abb4f16e50f545c886f24 · Passage 310b86878554e81bdb146781584106ecf5e85a12bab1a245a07c724a19041d84 · Zeichen 4762–6733 im Abschnitt